dc.contributor.author | Sternberg, Cora N. | en |
dc.contributor.author | Huinink, W. W. Ten Bokkel | en |
dc.contributor.author | Smyth, J. F. | en |
dc.contributor.author | Bruntsch, V. | en |
dc.contributor.author | Dirix, L. Y. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Franklin, H. R. | en |
dc.contributor.author | Wanders, S. | en |
dc.contributor.author | Bail, N. Le | en |
dc.contributor.author | Kaye, Stanley B. | en |
dc.creator | Sternberg, Cora N. | en |
dc.creator | Huinink, W. W. Ten Bokkel | en |
dc.creator | Smyth, J. F. | en |
dc.creator | Bruntsch, V. | en |
dc.creator | Dirix, L. Y. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Franklin, H. R. | en |
dc.creator | Wanders, S. | en |
dc.creator | Bail, N. Le | en |
dc.creator | Kaye, Stanley B. | en |
dc.date.accessioned | 2018-06-22T09:53:18Z | |
dc.date.available | 2018-06-22T09:53:18Z | |
dc.date.issued | 1994 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41765 | |
dc.description.abstract | Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: Liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma. © Macmillan Press Ltd., 1994. | en |
dc.language.iso | eng | en |
dc.source | British journal of cancer | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Fatigue | en |
dc.subject | Multicenter study | en |
dc.subject | Neurotoxicity | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Phytogenic | en |
dc.subject | Stomatitis | en |
dc.subject | Drug administration | en |
dc.subject | Drug administration schedule | en |
dc.subject | Fever | en |
dc.subject | Docetaxel | en |
dc.subject | Dose response | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Male | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Statistical analysis | en |
dc.subject | Vomiting | en |
dc.subject | Colorectal carcinoma | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Blood toxicity | en |
dc.subject | Nausea | en |
dc.subject | Liver metastasis | en |
dc.subject | Lung metastasis | en |
dc.subject | Drug activity | en |
dc.subject | Corticosteroid | en |
dc.subject | Antihistaminic agent | en |
dc.subject | Steroid | en |
dc.subject | Drug derivative | en |
dc.subject | Middle age | en |
dc.subject | Drug screening | en |
dc.subject | Skin toxicity | en |
dc.subject | Edema | en |
dc.subject | Headache | en |
dc.subject | Adjuvant chemotherapy | en |
dc.subject | Colorectal tumor | en |
dc.subject | Abdominal mass | en |
dc.subject | Hypersensitivity | en |
dc.subject | Premedication | en |
dc.title | Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1038/bjc.1994.309 | |
dc.description.volume | 70 | |
dc.description.issue | 2 | |
dc.description.startingpage | 376 | |
dc.description.endingpage | 379 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |